Thomas De Shazo Email & Phone Number

Eagle, Id, Us

New York, New York, United States

Neurotherapeutic Clinical Studies and Applied Translational CNS Research. Molecular’s therapeutic mechanisms of action (MOA) and methods of action (MoA) are not limited to treating the pathophysiology of traumatic brain and acute central nervous system injury, but also apply to pathophysiological dysfunctions in other neurodegenerative and CNS diseases. These dysfunctions include inflammasome (cytosolic multiprotein oligomers) therapeutic targets and diagnostic biomarkers in neurodegenerative and acute central nervous system injury. TBI and mTBI (concussions) inflammasome activation in response to neurological insults, CNS, and neurodegenerative disorders and diseases.Molecular’s therapeutics reduce the biomolecular processes (intercellular transcription factors) linked to pro-hyperinflammatory response molecules and signaling pathways (interferons, interleukins, TNF-a, NF-κB, IFN-regulatory factor 3 (IRF3), Janus kinases (JAK- STAT1) and the reduction of deregulated molecular mechanisms and epigenetic processes by inhibiting mitochondrial free radicals (superoxide anions (O2), hydroxyl radicals (OH), lipoperoxide radicals (LO2), nitric oxide radicals (NO), and nitrogen dioxide radicals (NO2) singlet oxygen, peroxynitrite) that play an important role in diseases such as arthritis rheumatoid, osteoarthritis; systemic lupus erythematosus (SLE); and conditions of the extracellular matrix synthesis and blunting the degradation of complex oxidative stress signaling pathways, and halting virus-induced production of OS, ROS, RNS in cytokine (cascades) storm, and attenuating lung host cell’s metabolism redox imbalance (ADP/ATP, NAD+/NADH, and NADP+/NADPH ratios).In escalating fixed-dose combination clinical studies, Molecular’s formulation’s PK and PD (safety and efficacy) from 10,000+ assays, cellular absorption, and bioavailability of 20+ hours) will be referenced in an FDA Phase 2a Clinical Trial.

Washington, D.C.

Advocatus represents sovereign nations, their state-owned entities, commercial entities, and individuals.Our attorneys and professionals possess extensive experience spanning decades with a proven track record securing substantial judgments, awards, and settlements, ranging from tens of millions to billions of U.S. dollars, in international commercial litigation, investor bilateral investment treaty claims, and arbitration, representing clients in complex multijurisdictional and transnational matters in the United States, Europe, the Middle East, Africa, Latin America, and Asia.Within the international legal community, we have the privilege of collaborating with Band 1 global law firms as co-counsel in multifaceted representation that provides our clients with an invaluable array of resources, strategies, and guidance to successfully navigate complex global legal disputes.Our lawyers have been recognized for their advocacy in the field of human rights, earning recognition for their representation in Africa, Europe, and the United Kingdom. They have spearheaded and effectively managed numerous high-profile cases involving prominent “victim” led justice and human rights actions on a global scale. Notable examples include litigation against entities such as the IRA, RIRA, Aqsa Martyrs, Hamas, IS, Ghaddafi, Iran, Lukashenko, and recent efforts on behalf of the victims of the Rohingya genocide. The above underscore our unwavering commitment to championing human rights and advocating for those affected by grave injustices.The firm’s attorneys have appeared in significant cases before the U.S. Supreme Court, U.S. District Courts and U.S. Circuit Courts of Appeals, the Court of Justice of the European Union, ICSID, and UNCITRAL arbitration tribunals, and members of U.S. Delegation to UNCITRAL Working Group III on Investor-State Dispute Settlement (WGIII) and the U.S. State Department's Advisory Committee on Private International Law (ACPIL).

New York City Metropolitan Area

Molecular has patented and patent-pending CNS and Neurotherapeutics.Research supports our drugs will attenuate Nrf2 activation by restoring lysosome levels and increasing autophagic clearance, reduce inflammation and immune responses including reactive microgliosis, decrease proinflammatory cytokine expression, and eliminate fibrillar aggregates (oligomeric α-syn species) and accumulation of aggregated α-syn, prevent neuro oxidative damage, attenuate OS (ROS/RNS) induced by Aβ and HNE, as shown in cultured neuronal cells. This suggests depletion of our bioavailable molecules exacerbate oxidative insults stimulated by Aβ and accelerates the development of the disease. Our molecules depletion in SN dopaminergic neuronal cells is a key mechanism within onset and progression of PD, associated protein aggregation which form Lewy bodies and dysfunction from the inhibition of complex I activity and oxidative damage, including protein oxidation, and deleterious effects of lipid peroxidation by-product 4HNE. The pathophysiology through mechanisms including the induction of oxidation of macromolecules such as nucleic acids, proteins, lipids, mitochondrial dysfunction, glial cell activation, amyloid β deposition, apoptosis, and proteasome dysfunction, are directly related to our compound's action. The pathophysiology of DD through a variety of mechanisms including the induction of oxidation of macromolecules such as nucleic acids, proteins, lipids, mitochondrial dysfunction, glial cell activation, amyloid β deposition, apoptosis, and proteasome dysfunction is shown to be regulated by the molecules within our formulations. Further depletion of our drug molecules causes the indirect formation of endotoxins in the cytoplasm of pigmented SN cells that contribute to the degeneration of these neurons in PD. (protein folding, synucleinopathies neuroinflammation, tauopathies, and aggregation (OS crosstalk in Tauopathy, hyperphosphorylation, polymerization, and toxicity).

New York City Metropolitan Area

SARS-CoV-2 (COVID-19): Molecular's patented and patent-pending formulations are compelling COVID-19 therapeutics. Our drug targets Oxidative stress (OS) and Reactive oxygen species (ROS) responses that are the underlying cause of systemic tissue damage in SARS-2. Both the innate and adaptive immune responses are established in the pathogenesis of COVID-19, and its activated neutrophils, macrophages, and monocytes cells that produce damaging ROS by creating an imbalanced oxidative stress response and endogenous molecule's oxidation that triggers the pro-inflammatory cytokine storm.Most importantly the ROS imbalance activates (Toll receptor signaling) transcription factor NF-κB. Imbalanced ROS suppresses the T cell response and significantly reduces antiviral CD8 (CD4) T cells necessary to reduce viral load, viral replication, and kill infected cells. Within the above mechanisms are TNF-α and IL-1β and TLR4 signaling to NF-kB inflammatory responses. Oxidative stress is the underlying pathogenesis to acute COVID-19 illness, and it is proposed and supported by hundreds of recently published research that our plasma bioavailable therapeutic would directly attenuate ROS and increase mitochondrial and blood plasma total antioxidant capacity.

Greater New York City Area

LDJ Capital is a multi-family office that invests and manages investments for partners and clients in the areas of hospitality, real estate, energy, pharma, tech, telecom, mobile, entertainment, media, publishing, advertising, compliance services, aerospace, shipping & transportation, and more recently digital assets, such as cryptocurrency and blockchain firms through ICOs.

Avira Sciences (formerly TTDC BIO S.a.r.l.), is a drug and therapeutic life science company with global patented and patent pending pharmaceutical and biological therapeutic solutions for the treatment of diabetes, infectious, cancer, immunological and other human diseases. Avira Sciences identifies world-class scientists and life science technologies and provides financial, management, and legal resources for commercialization. Avira’s mission is to discover innovative drug and cellular therapeutic solutions for the treatment of human and animal diseases and disorders. A drug and therapeutic delivery platform was the founding technology of Avira Sciences in Luxembourg in2005.Avira's latest clinically proven patent-pending technology is based upon a class of LONG-ACTING AND ULTRA LONG-ACTING INJECTABLE INSULIN human recombinant formulations that will be marketed for one third the price of other analogous long-acting injectable insulin.LONG-ACTING AND ULTRA LONG-ACTING INJECTABLE INSULINAvira Therapeutics has developed a new approach to dramatically extend the duration of action of commercially available injectable formulations based on therapeutic peptides, proteins, oligonucleotides, and polynucleotides. The prolongation effect of Avira’s technology uses novel proprietary Absorption Inhibiting Compounds that have never been formulated within pharmaceutical therapeutics. Avira’s Absorption Inhibiting Compounds are within the list of compounds Generally Recognized as Safe (GRAS) and included in all national Pharmacopoeias.“The lack of access to affordable insulin remains a key impediment to successful treatment and needless complications and premature deaths” Global report on diabetes © World Health Organization 2016

Greater New York City Area

Boise, Idaho

New York, New York

Boise And New York City

Luxemberg And Boise, Idaho Area,

Bermuda, Moscow, Ukraine, And U.S.

Cyprus, Moscow

New York, Moscow, Kiev, St. Petersburg, Almaty, Novosibirsk

Cyprus, Moscow, Calgary, Houston, Geneva, London